BioNxt Solutions Inc. has proudly announced the acquisition of advanced coating and cutting equipment, marking a crucial stride in expanding its commercial manufacturing of drug delivery products.
The newly acquired machinery is poised to elevate the production of drug delivery products at the Vektor Pharma TF GmbH facility situated in Baden-Württemberg, Germany.
The cornerstone of this expansion is the state-of-the-art coating machine, meticulously designed and manufactured in Germany.
What sets this machinery apart is its full automation, coupled with sensor-controlled coating thickness measurement capabilities. This cutting-edge feature ensures precision and efficiency in the coating process, setting a new standard in pharmaceutical manufacturing.
Complementing the coating machine is an equally sophisticated cutting machine, also crafted in Germany. Boasting full automation and camera-controlled laser cutting, this equipment incorporates pick-and-place robot automation.
The seamless integration of these technologies not only streamlines the manufacturing process but also enhances overall productivity. Importantly, both machines adhere to the highest safety and environmental standards, being CE-certified under European regulations.
How will the technology optimise drug delivery?
This cutting-edge equipment is specifically tailored for the production of BioNxt’s oral dissolvable (ODF) and transdermal (TDS) drug formulations.
These formulations, designed to revolutionise drug delivery, have garnered attention for their non-invasive nature and effectiveness in treating pain and neurological conditions.
BioNxt’s wholly owned subsidiary, Vektor Pharma TF GmbH, based in Baden-Württemberg, Germany, has been at the forefront of narcotics manufacturing, development, and research.
For more than a decade, the company and its dedicated team have led the way in designing, testing, and manufacturing innovative non-invasive drug delivery systems.
Notable among these are transdermal patches and sub-lingual strips, which have proven efficacy in delivering active pharmaceutical ingredients.
Hugh Rogers, BioNxt CEO & Director, emphasised the significance of the equipment: “BioNxt is focused on expedited development of its lead ODF and TDS drug formulations.
“With these products advancing toward commercialisation and with potential contract development and manufacturing opportunities available, the company is committed to achieving in-house commercial manufacturing capability as soon as possible.”
Capturing the growing market
The expansion comes at a strategic time as the global pharmaceutical drug delivery market is experiencing rapid growth.
According to Precedence Research, the market size reached $1.525bn in 2022 and is projected to exceed approximately €2.047bn by 2030.
BioNxt’s latest investment in cutting-edge manufacturing equipment positions the company well to meet the increasing demand for innovative drug delivery solutions, reinforcing its commitment to advancing healthcare through technology and research.
